The market has climbed by 5.8% over the past week, and is up 4.8% over the past year, with earnings expected to grow by 14% per annum in the coming years. Though the term 'penny stock' might sound ...

CureVac N.V.'s restructuring deal with GSK and workforce reduction suggest financial struggles, with net losses reported from 2020-2023; however, the GSK deal secures funding until 2028.

CureVac Trading Down 2.5 % Shares of NASDAQ:CVAC opened at $3.12 on Monday. The business has a 50 day moving average of $3.08 and a two-hundred day moving average of $3.17. The company has a ...

Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac said: "The fourth quarter of 2024 marked a strong finish to a year of significant transformation for CureVac.

The live webcast link can be accessed via the newsroom section of the CureVac website at https://www.curevac.com/en/newsroom/events/ Corresponding presentation slides ...

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solely responsible for the content of this ...

CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, expectations were $-0.14. Operator: Greetings.

Greetings. Welcome to CureVac Fourth Quarter and Full Year 2024 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session ...

CureVac (CVAC) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase 1 clinical study of CVHNLC in patients with squamous non-small ...